Literature DB >> 1888202

Interleukin 2 production in a family with systemic lupus erythematosus and a C4Q0 heterozygous inheritance.

C Gutierrez1, E Cabrero, J L Vicario, M Martín Villa, M A Rengel, F J Gomez Campdera, M Yebra, E Fernández-Cruz, A Arnaiz Villena.   

Abstract

Interleukin 2 production was studied in a family with systemic lupus erythematosus (SLE) and a C4Q0 heterozygous inheritance. Autoimmune manifestations seemed to be associated with the HLA haplotype containing the C4Q0 allele, which was shared by all four ill family members. Concentrations of interleukin 2, however, did not associate either with the haplotype or with the clinical or serological manifestations, as diminished concentrations of interleukin 2 were found in only two subjects with SLE. Thus the defect in this family seemed to be acquired rather than genetically conditioned.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888202      PMCID: PMC1004493          DOI: 10.1136/ard.50.8.579

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

2.  Immunofixation for C2 typing: C2 allotypes in Spaniards in relation to HLA, Bf and C4.

Authors:  J R Regueiro; A Arnaiz-Villena
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

3.  Bf polymorphism and its relationship with HLA antigens in a sample of the Spanish Population: high BfF1 frequencies.

Authors:  S Rodriguez-Córdoba; A Bootello; A Arnaiz-Villena
Journal:  Tissue Antigens       Date:  1981-02

Review 4.  The role of interleukin 2 in autoimmunity.

Authors:  G Kroemer; G Wick
Journal:  Immunol Today       Date:  1989-07

5.  Abnormal production of and response to B-cell growth factor and B-cell differentiation factor in patients with systemic lupus erythematosus.

Authors:  T Hirose; M Hara; A Kitani; W Hirose; K Norioka; M Kawagoe; H Nakamura
Journal:  Scand J Immunol       Date:  1985-02       Impact factor: 3.487

6.  Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells.

Authors:  M Linker-Israeli; A C Bakke; F P Quismorio; D A Horwitz
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

7.  Deletion of C4A genes in patients with systemic lupus erythematosus.

Authors:  M E Kemp; J P Atkinson; V M Skanes; R P Levine; D D Chaplin
Journal:  Arthritis Rheum       Date:  1987-09

8.  Stimulating and differentiation factors for human B lymphocytes in systemic lupus erythematosus.

Authors:  E Martinez-Cordero; J Alcocer-Varela; D Alarcon-Segovia
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

9.  Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.

Authors:  Y Murakawa; S Takada; Y Ueda; N Suzuki; T Hoshino; T Sakane
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

10.  The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells.

Authors:  Y P Huang; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.